Novo Nordisk Submits Investigational Sickle Cell Disease Therapy Etavopivat to FDA and EMA for Approval

Novo Nordisk announced on November 13, 2026, the submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) and a Marketing Authorization Application (MAA) to the European Medicines Agency (EMA) for etavopivat. This investigational, once-daily, orally available therapy is intended for adolescents and adults (aged 12 years and older) living with sickle cell disease (SCD). The submissions are supported by data from the Phase 3 HIBISCUS trial, which demonstrated the efficacy and safety of etavopivat. If approved, etavopivat could offer a new disease-modifying treatment approach for SCD, a progressive and debilitating blood disease with limited therapeutic options. The FDA has previously granted etavopivat Fast Track, Rare Pediatric Disease, and Orphan Drug designations, with action on the NDA expected in 2027.

Context

Sickle cell disease is a hereditary blood disorder that causes severe pain and various health complications. Current treatments primarily focus on managing symptoms rather than modifying the disease itself. Novo Nordisk's etavopivat has shown promise in clinical trials, particularly in the Phase 3 HIBISCUS trial, which supports its efficacy and safety for patients aged 12 and older. Regulatory bodies like the FDA and EMA play crucial roles in evaluating new therapies for public health.

Why it matters

The submission of etavopivat for regulatory approval is significant as it represents a potential advancement in the treatment options for sickle cell disease, a condition that affects many individuals worldwide. Current therapies are limited, and etavopivat may provide a new disease-modifying approach that could improve patient outcomes. This could lead to enhanced quality of life for those living with this debilitating disease.

Implications

If approved, etavopivat could transform the treatment landscape for sickle cell disease, providing patients with a new option that may alter the course of the disease. This development could also influence future research and investment in therapies for rare diseases. Patients, healthcare providers, and insurers may all be affected by changes in treatment protocols and healthcare costs associated with new therapies.

What to watch

The FDA and EMA will review the submitted applications, with the FDA expected to take action in 2027. Stakeholders will be monitoring the review process closely for updates on the approval status. Additionally, the response from the medical community and patient advocacy groups will be important in shaping the discourse around etavopivat's potential impact.